Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urinary Bladder Neoplasms × lirilumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Leukemia, Myeloid, Acute 2 Leukemia 2 Urinary Bladder Neoplasms 1 Recurrence 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Melanoma 1 Leukemia, Lymphoid 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, Biphenotypic, Acute 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Cancer 1

Interventions

Gemcitabine 133 Cisplatin 98 pembrolizumab 70 Cystectomy 41 Paclitaxel 38 Docetaxel 37 Carboplatin 37 Nivolumab 36 Mitomycin 33 durvalumab 29 atezolizumab 29 Radiotherapy 28 Magnetic Resonance Spectroscopy 28 avelumab 23 Specimen Handling 23 Cystoscopy 22 BCG Vaccine 21 Doxorubicin 20 Fluorouracil 18 enfortumab vedotin 16 Methotrexate 15 Vinblastine 14 Standard of Care 14 5-aminolevulinic acid hexyl ester 14 Ipilimumab 13 Filgrastim 13 vinflunine 12 Biopsy 12 Transurethral Resection of Bladder 11 Surgical Procedures, Operative 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03532451 2024-09-19

PrE0807

PrECOG, LLC.

Phase 1 Completed

43 enrolled 15 charts

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡